RNA NASDAQ
Atrium Therapeutics, Inc.
1W: -5.4%
1M: -44.2%
3M: -39.7%
YTD: -89.1%
1Y: -82.0%
3Y: +22.9%
5Y: -67.7%
$7.84
-0.30 (-3.69%)
Weekly Expected Move ±11.5%
$6
$7
$8
$9
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2026-02-27
Earliest Filing
2026-02-27
Latest Filing
partner: 3
Counterparties (Filed by RNA)
3 relationshipsCompanies named in RNA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Avidity Biosciences, Inc. | — | partner | Parent company that spun off Atrium Therapeutics and entered into license and transition service agreements. | 2026-02-27 | View |
| Bristol-Myers Squibb Company | — | partner | Collaboration partner whose agreement was transferred to the spun-off company. | 2026-02-27 | View |
| Eli Lilly and Company | LLY | partner | Collaboration partner whose agreement was transferred to the spun-off company. | 2026-02-27 | View |
Recent 8-K Filings (5)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-07-14 | Other Events; Exhibits | View | |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-02-27 | Entry into Material Definitive Agreement; Changes in Control of Registrant; Departure/Election of Di | Agreement | View |
| 2026-02-26 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR